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1. Introduction: the RNA world
We have already learned how the genetic codes or biological information are transcribed into 
mRNAs, and then how they are translated into amino acid sequences of various polypeptides. 
This is widely known as “Central Dogma”, the most fundamental and important concept 
in molecular biology. In the translation process, polypeptides are synthesized by ribosomes 
with a template mRNA. Thus, in this context, we tend to take it for granted that the main func-
tion of RNAs is just transporting genomic information from nuclei to cytoplasm. However, if 
we regard a ribosome as a polypeptide-synthesizing protein-RNA complex, which contains 
all major RNAs, mRNA, rRNA, and tRNA, we will realize that the RNAs have biologically 
important roles as enzymatic machinery to synthesize proteins. RNAs are not only required 
for the translation system, but also for splicing/processing of RNAs and telomere elonga-
tion, contained in the protein-RNA complexes, snRNPs, and TERC subunit of the telomerase, 
respectively. Moreover, recent studies revealed that non-coding RNAs (ncRNAs, siRNAs, or 
miRNAs) regulate transcription and translation.
Because, as described, RNAs have both information and function, it is suggested that they 
might have been the most fundamental and primary molecules from the beginning of chemi-
cal evolution before living organisms emerged on earth. Even in the DNA replication process, 
RNAs are required as primers for the leading strand synthesis. Recent study in initiation 
site sequencing (ini-seq) revealed that the human DNA replication origins very frequently 
overlap with transcription start sites (TSSs) and G-quadruplex (G4) motifs [1]. In other words, 
a number of biologically essential events or reactions are dependent on the synthesis of the 
RNA molecules. Thus, it has been proposed that an origin of life has come from an “RNA 
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World” [2], which might have given a chance to develop the most biologically essential reac-
tions for life, including replication, transcription, and translation.
Based on the concept that RNAs are the most essential molecules for living things, in this book 
project, it is worth to focus on topics discussing on how transcription is regulated and how it 
becomes if it is dysregulated.
2. Transcriptional controlling system in eukaryotic cells
It is already known that three types of RNA polymerases participate in the synthesis of differ-
ent types of RNAs. The RNA polymerase (RNA pol) I and III catalyzes production of rRNAs, 
tRNAs, and snRNAs. Although they are essentially important enzymes to generate functional 
RNAs, much of the interest have been directed to RNA pol II, which catalyzes both protein-
encoding and non-coding gene transcription. Up to present, molecular mechanisms of how 
each protein-encoding gene is expressed have been well studied. Most of the textbooks in 
molecular biology describe in detail how general transcription factors, including TBP, TFIIB, 
TFIID, TFIIE, TFIIF, and TFIIH, co-operatively work to recruit RNA pol II appropriately onto 
the TSSs [3]. Recently, structure of the eukaryotic RNA pol II complex, containing elongation 
factors, Spt4/5, Elf1, and TFIIS, has been revealed [4]. The entire transcription reaction system 
from initiation to termination on DNA template will be elucidated in the near future.
In eukaryotic cells, epigenetic regulation or chromatin modification affect gene expres-
sion. After unwinding the chromosomes, each gene will be correctly transcribed from TSS 
in the core promoter region. The promoter activity is regulated by enhancer or proximal 
promoter regions, where various transcription factors (TFs) access to bind. These TFs usu-
ally recognize specific DNA sequences or cis-elements, and the enhancement of transcrip-
tional activity is dependent on the combinations of TFs, their binding sites, or distances 
from TSS. Thanks to the completion of human genome project, and with a development 
of Next Generation Sequencing (NGS) and especially Chromatin Immune Precipitation 
sequencing (ChIP-seq) technique [5], we can now refer TF-binding sequences and TSSs 
of most of the genes by a number of online programs, including NCBI, JASPAR, and 
DBTSS databases [6–8]. Promoters and enhancers, which might be digital landmarks on 
genomes for TFs, can determine transcription-initiation frequency. After transcription is 
completed, RNAs should be appropriately processed and modified. These processes are 
regulated by RNA binding helicases and ncRNAs [9]. It should not be ignored that RNAs 
are degraded in RNA exome complexes [10]. The degradation is required for the quality 
control of RNAs and gene expression. Then, mRNAs are incorporated in mRNPs that 
are to be exported from nuclei to cytoplasm with a help of export-component proteins, 
including TREX [11]. Thus, matured mRNA molecules are made through a complicated 
multistep process, though it would be advantageous for cells to fine tune gene expression 
system overall. If unpredictable and undesired expression of some specific genes hap-
pened, it may lead to dysfunctions in mitochondria, immune response, and DNA-repair/
epigenetic controlling systems. If it were deleterious for organisms, it may cause diseases, 
including cancer.
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3. Non-coding RNAs (ncRNAs)
Not all of the information on the genomes encodes protein. It is estimated that most (about 
95%) of the genomes consist of non-coding regions. Recent transcriptome analyses, including 
Cap-Analysis Gene Expression (CAGE), revealed that large amount of ncRNAs are contained 
in total transcripts [12]. Because ncRNAs do not encode proteins, they have long been thought 
as “junks” in the genome. However, recent studies discovered that some of them are not 
junks, rather “jewels” in nuclei having essential roles in controlling cell growth, development, 
and function. The ncRNAs are classified into two groups as short ncRNAs (miRNAs, piwiR-
NAs, and snRNAs) and long ncRNAs (lncRNAs), consisting of over 200 ribonucleotides in the 
molecule. The more analytical methods in sequencing RNA molecules developed, the more 
lncRNAs were identified with increasing in number, which are estimated over 35,000 at pres-
ent. The lncRNAs are transcribed by RNA pol II, and their TSSs are frequently (65%) found 
at bidirectional promoter regions [13]. In mouse embryonic cells, transcribed lncRNAs recruit 
TFs and splicing factors to activate neighboring or bi-directional partner gene expression [14]. 
Therefore, lncRNAs may give accurate platforms or TSSs for bi-directional partner genes. 
Recent study with genome editing system identified lncRNA loci regulate genes neighbor-
hood [15]. In addition, it was revealed that specific lncRNAs are contained in nuclear bodies, 
including nuclear speckle (MALAT1), paraspeckle (NEAT1), and polycomb body (TUG1) [16], 
suggesting that lncRNAs affect chromosomal integrity. More importantly, the lncRNAs have 
certain effects on epigenetic gene regulation systems [17]. The famous example is that X inac-
tive specific transcript (Xist) silences X chromosome genes, interacting with transcriptional 
suppressor proteins [18]. Not only Xist, but also other lncRNAs, such as HOTAIR, LUNAR1, 
and MALAT1 are required as scaffolds for DNA methylation/demethylation factors, chro-
mosome looping factors, and splicing factors, respectively [17]. Additionally, enhancer RNA 
(eRNA), which is transcribed at active enhancer, can function as a scaffold for histone aceth-
yltransferase CBP to modulate gene expression [19].
4. Epigenetic control of gene expression
Gene expression pattern could be altered by epigenetic regulation [20]. The epigenetic con-
trol, which mainly regulates expression of sets of genes, is driven by DNA methylation, 
histone modifications, chromatin remodeling, and ncRNAs [20, 21]. A lot of factors that 
are involved in the epigenetic controlling system have been identified and characterized. 
Methyl groups could be transferred to both DNAs and histone proteins by enzymatic reac-
tions. DNA methylation plays pivotal roles in the regulation of nuclear events, including 
gene expression [22]. Especially, when silencing of DNA repair genes occurred, it may boost 
mutation rate, and it will be resulted in the genome instability. Therefore, DNA methyla-
tion is regarded as one of the essential biomarkers in cancer [23]. The reaction is catalyzed 
by at least three independent DNA methyltransferases (DNMTs): DNMT1, DNMT3A, and 
DNMT3B [24], using S-adenosyl-l-methyonine (AdoMet) as a methyl group donor [25]. 
The ten-eleven translocation (TET) family proteins, including TET1, TET2, and TET3, are 
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the 5-methylcytosine hydroxylases that remove methyl group from an oxidized form of the 
cytosine (5mC), 5-hydroxymethylcytosine (5hmC), and other forms [20, 22]. Recent study 
revealed that intragenic DNA methylation assists fidelity in genome transcription initiation 
[26]. NRF protein preferentially accesses to unmethylated genomic regions, indicating that 
DNA methylation status restricts binding of methylation sensitive TFs onto their recognition 
sequences [27]. A methylation sensitive SELEX analysis indicated that transcription factor 
ETS protein binding was inhibited by mCpG, but homeobox proteins, such as POU and 
NFAT, preferentially bind to the methylation introduced site [28]. The results suggest that 
DNA recognition mechanism of several TFs that mainly act in the development of organisms 
is dependent on the methylation of DNA.
Histone proteins could be modified by attachment of various molecules, including methyl-, 
acetyl-, hydroxyl-, SUMOyl-, and poly ADP(ribosyl)-groups [20, 29]. In addition, they are 
acylated on the Lys residues to regulate transcription of genes that encode metabolic-response 
factors [30]. These modifications are recognized by different proteins, such as bromodomain-
containing proteins [31], double PHD finger domain proteins [30, 32], YEATS domain pro-
teins [30], WD40 proteins [33], and Ankyrin-repeat proteins [34].
As described above, epigenetic regulation is tightly linked with genome stability, and it is 
affected by modifying group molecules or metabolites, including acetyl-CoA, AdoMet, and 
NAD+ [35]. These observations suggest that aging is not only determined by genetic infor-
mation, but also by environmental stresses, including nutrient conditions [36]. Interestingly, 
recent study indicated that lactate dehydrogenase LDHA promotes IFN-γ expression through 
an epigenetic mechanism [37]. The results suggest that LDHA-mediated aerobic glycolysis 
could enforce mitochondria to generate more acetyl-CoA that is to be utilized for histone 
modification. Poly(ADP-ribosyl)ation is a protein modification reaction that is catalyzed by 
PARP enzymes using NAD+ as a substrate. The poly(ADP-ribosyl)ation occurs on histones, 
non-histone proteins, DNA-repair factors [38], and TFs to regulate gene expression [39, 40]. In 
summary, nutrients or food intake may have some roles in regulating transcription because 
they can induce epigenetic changes [41].
5. Transcription disorders and human diseases
The great progresses in the whole genome sequencing (WGS) techniques enabled us to study 
subtle differences in genomic sequences between cancer and normal cells [42]. Somatic muta-
tions on driver genes in various cancers have been identified [43] and the statistical data 
will be applied on diagnosis or even on the prediction of cancer risks and incidences [44]. 
Very recently, it was proposed that analysis of WGS data from circulating tumor cells could 
be applied for personalized therapy for malignant cancer [45]. Importantly, mutations in 
5′-upstream region of the human TERT gene are frequently identified in melanoma [46, 47]. 
It should be noted that in certain cancers, especially in melanomas, the rate of somatic muta-
tions is highly increased at active TF-binding sites, where they interfere accession of nucleo-
tide excision repair (NER) machinery [48, 49]. Thus, cancer-related mutations are not only 
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present in the protein-coding regions, but also in the gene expression regulatory regions, 
including promoters and enhancers in the genomes.
Various diseases may be caused by dysregulations in transcription. For example, Yes-associated 
protein (YAP) and TAZ proteins, which activate inflammatory gene expression, are involved 
in the atherosclerosis [50]. In several neurological and neuromuscular disorders, including 
Huntington disease, muscular dystrophy, and amyotrophic lateral sclerosis (ALS), accumula-
tion of repeat containing RNAs in aberrant foci in nucleus have been observed [51]. Moreover, 
shRNA screening system in vitro showed that transcription elongation factors, including JMJD6, 
help cells to survive in the microenvironment of glioblastoma [52]. The result suggests that 
the transcription elongation machinery could be an effective therapeutic target. It was recently 
reported that ENL protein, which possesses acetyl lysine recognizing YEATS domain [30], acts 
as an activator of leukemia-diving factor encoding gene expression [53, 54]. Therefore, target-
ing the ENL protein could be an effective therapeutic strategy against aggressive leukemia. 
Currently, candidate drugs that target HDAC [55–57] and DNMTs [56, 57] are under clinical 
tests and expected to contribute to the development of novel cancer therapeutics. Epigenetic 
alterations on genomic DNAs is not only associated with cancer generation, but also with neu-
rologic diseases [58], autoinflammatory diseases [59], and metabolic diseases, including type II 
diabetes [60]. Toward establishment of new therapies for these diseases, epigenetic modulators 
will be the right targets for effective treatment with lowered side effects [61]. We should remem-
ber drug resistance of cancer could be caused by compounds that induce epigenetic reprogram-
ming, and thereby alter transcriptional state, which is regulated by SOX proteins, Jun/AP1, and 
GGAA-recognizing factors [62]. Therefore, secondly effects of drugs on transcription system 
should be examined. In summary, next generation therapeutics may have to put gene expres-
sion systems under control.
6. Future prospects
Overall, most of the cellular responses to signals and stresses from the environment, includ-
ing DNA damage, nutrient condition, viral infections, and some specific drugs, could affect 
transcription or gene expression profile. Presently, it has been shown that introduction of 
several TFs (OKSM factors or Yamanaka factors) into somatic cells can reprogram and convert 
them with pluripotency [63, 64]. Very recently, it was experimentally shown that iPS cell-
derived dopaminergic neurons could be applied for the treatment of Parkinson’s disease [65]. 
These experimentally supported evidences suggest that introduction of certain combination 
of TFs into cancer cells might enforce them to reprogram transcription profile so that they 
could stop proliferation but acquire DNA repair with more accuracy.
Clinical application of gene therapy [66] with appropriate set of expression vectors to induce 
DNA repair or mitochondrial function associated genes will soon be established. Not only 
vectors, which deliver TF-encoding genes into cell nuclei, but also nucleic acids, including 
siRNAs, lncRNAs, or RNA aptamers, should be also improved for the strategy. In addition, 
genome editing on the promoter or enhancer regions of some target genes of patient derived 
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cells will be an effective approach to treat specific diseases. For example, it was recently 
reported that genome editing to delete α-globin enhancer reduces its excessed expression in 
primary human hematopoietic stem cells, strongly suggesting the clinical use of the technique 
could be applied as a potential therapy for β-thalassemia [67]. Therefore, genome editing on 
transcription regulatory elements will be an alternative novel gene therapy for leukemia and 
cancer, in accordance with a progress in gene delivery system. In the near future, the continu-
ing studies in the transcription controlling systems will successfully contribute to establish 
novel therapeutics for various human intractable diseases, including cancer, immunological 
diseases, and neuro-degenerating diseases.
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